Metagenomi Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(In thousands)

	Six Months Ended June 30,
	2024	2023
Cash flows from operating activities
Net loss	$(35,887)	$(29,141)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	9,569	1,185
Depreciation	2,582	1,852
Loss on fixed assets write-off	279	—
Non-cash lease expense	2,264	2,042
Amortization of premiums and discounts on available-for-sale marketable securities	(3,201)	(4,536)
Amortization of non-cash collaboration revenue	(107)	(507)
Change in fair value of long-term investments	—	(2,870)
Changes in operating assets and liabilities:
Accounts receivable	803	(2,328)
Contract assets	—	1,274
Prepaid expenses and other assets	(274)	21
Accounts payable	1,734	882
Income tax payable	(3,266)	1,178
Deferred revenue and collaboration advance	(29,419)	(16,161)
Accrued expenses and other current liabilities	340	72
Operating lease liabilities	(300)	(717)
Other non-current liabilities	(1,276)	667
Net cash used in operating activities	(56,159)	(47,087)
Cash flows from investing activities
Purchases of property and equipment	(1,580)	(5,818)
Purchases of available-for-sale marketable securities	(249,166)	(168,977)
Maturities of available-for-sale marketable securities	142,978	84,008
Net cash used in investing activities	(107,768)	(90,787)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs	84,505	—
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	—	4,295
Payments of initial public offering costs	—	(39)
Net cash provided by financing activities	84,505	4,256
Net decrease in cash, cash equivalents and restricted cash	(79,422)	(133,618)
Cash, cash equivalents and restricted cash at beginning of period	145,851	190,514
Cash, cash equivalents and restricted cash at end of period	$66,429	$56,896
Supplemental disclosure of non-cash information
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$350,758	$—
Issuance of common stock and restricted common stock in exchange for profits interests upon Reorganization	$9,457	$—
Initial public offering costs included in accounts payable, accrued expenses and other current liabilities	$492	$—
Reclassification of deferred offering costs paid in prior year to stockholders’ equity	$3,283	$—
Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities	$1,088	$1,593
Operating lease right-of-use assets obtained in exchange for new lease liabilities	$—	$30,608
Remeasurement of operating right-of use asset and lease liability	$12	$—
Deferred initial public offering costs included in accounts payable, accrued expenses and other current liabilities	$—	$1,621
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	$61,181	$51,648
Restricted cash	5,248	5,248
Cash, cash equivalents and restricted cash at end of period	$66,429	$56,896

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.